['plaque psoriasis']
['tazarotene cream 0.05%', 'tazorac® (tazarotene) cream 0.05%', 'placebo']

        Inclusion Criteria:

          -  Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis,
             involving at least 2% and no more than 20% of the body surface area (BSA) (not
             including the scalp and intertriginous areas)

          -  Have a minimum plaque elevation at the target lesion site of at least moderate
             severity (grade ≥ 3 on the Psoriasis Area Severity Index [PASI]). The most severe
             lesion at baseline should be identified as the target lesion

          -  Have an Investigator's Global Assessment (IGA) of disease severity of at least
             moderate (score ≥ 3) as an overall assessment of all lesions to be treated.

        Exclusion Criteria:

          -  A female subject who is pregnant, nursing, planning a pregnancy, or does not agree to
             use an acceptable form of birth control within the study participation period

          -  Have a current diagnosis of unstable forms of psoriasis in the treatment area,
             including pustular, guttate, exfoliative or erythrodermic psoriasis

          -  Have a history of psoriasis unresponsive to topical treatments
      